NASDAQ:CLVS Clovis Oncology - CLVS Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clovis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$0.08▼$0.1050-Day Range$0.08▼$1.0952-Week Range$0.08▼$3.32Volume1.16 million shsAverage Volume8.88 million shsMarket Capitalization$11.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability About Clovis Oncology (NASDAQ:CLVS) StockClovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Read More Receive CLVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CLVS Stock News HeadlinesFebruary 24, 2023 | marketbeat.comAnalysts Holding As Pfizer Waits On Two Phase 3 Studies (CLVS)Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.March 12, 2023 | bizjournals.comSilicon Valley Bank, a 'strong supporter' of Colorado tech startups, closed by regulatorsMarch 22, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastJanuary 30, 2023 | reuters.comCLVS.OJanuary 18, 2023 | seekingalpha.comCLVSQ Clovis Oncology, Inc.January 13, 2023 | forbes.comClovis OncologyJanuary 3, 2023 | wsj.comFirm Retention Summary: Clovis Oncology Inc.December 12, 2022 | reuters.comCancer drugmaker Clovis files for bankruptcy, hit by falling salesMarch 22, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastDecember 12, 2022 | benzinga.comThinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?December 12, 2022 | bizjournals.comBoulder drugmaker Clovis Oncology files for bankruptcyDecember 12, 2022 | finance.yahoo.comClovis Plans to Sell Cancer Drug to Novartis in Bankruptcy DealDecember 12, 2022 | finance.yahoo.comClovis (CLVS) Files for Bankruptcy Amid Lack of Financial AidDecember 12, 2022 | finance.yahoo.comClovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to NovartisDecember 12, 2022 | benzinga.comCancer Focused Clovis Oncology Files For BankruptcyDecember 12, 2022 | seekingalpha.comClovis stock slumps amid Chapter 11 filing, to sell FAP-2286 to Novartis for $50M upfrontDecember 12, 2022 | marketwatch.comClovis Oncology Shares Fall Premarket After Bankruptcy Filing >CLVSDecember 12, 2022 | finance.yahoo.comClovis Oncology stock slides 10% premarket after company files for bankruptcyDecember 12, 2022 | finance.yahoo.comClovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286December 12, 2022 | finance.yahoo.comU.S. drugmaker Clovis files for Chapter 11 bankruptcyDecember 12, 2022 | finance.yahoo.comUPDATE 1-Cancer drugmaker Clovis files for bankruptcy, hit by falling salesNovember 25, 2022 | finance.yahoo.comClovis (CLVS) Stock Down 50% in the Past 6 Months: Here's WhyNovember 21, 2022 | finance.yahoo.comDown 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)November 11, 2022 | finance.yahoo.comClovis Oncology Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 9, 2022 | finance.yahoo.comClovis Oncology Shares Nose-Dive As Potential Bankruptcy Filing LoomsNovember 9, 2022 | finance.yahoo.comClovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023November 9, 2022 | reuters.comClovis Oncology says could file for bankruptcy in 'very near term'See More Headlines Receive CLVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CLVS Company Calendar Last Earnings11/03/2021Today3/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLVS CUSIP18946410 CIK1466301 Webwww.clovisoncology.com Phone303-625-5000Fax303-245-0360EmployeesN/AYear Founded2009Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-264,520,000.00 Net Margins-189.37% Pretax Margin-189.68% Return on EquityN/A Return on Assets-57.78% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$148.76 million Price / Sales0.08 Cash FlowN/A Price / Cash FlowN/A Book Value($2.15) per share Price / Book-0.04Miscellaneous Outstanding Shares144,955,000Free Float138,577,000Market Cap$11.60 million OptionableOptionable Beta0.24 Social Links Key ExecutivesMr. Patrick J. Mahaffy MA (Age 55)Co-Founder, Chief Exec. Officer, Pres and Exec. Director Dr. Gillian C. Ivers-Read BSc (Age 64)Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations Mr. Daniel W. Muehl CPA (Age 54)Sr. VP of Fin. and Principal Financial & Accounting Officer Dr. Lindsey Rolfe BSc (Age 50)MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance Mr. Corwin Dale Hooks (Age 51)Chief Commercial Officer and Sr. VP Key CompetitorsInfinity PharmaceuticalsNASDAQ:INFICatalyst BiosciencesNASDAQ:CBIORegulus TherapeuticsNASDAQ:RGLSMolecular TemplatesNASDAQ:MTEMCingulateNASDAQ:CINGView All CompetitorsInsiders & InstitutionsJane Street Group LLCSold 32,800 shares on 2/15/2023Ownership: 0.000%Aristeia Capital LLCSold 325,000 shares on 2/15/2023Ownership: 0.000%Susquehanna International Group LLPSold 503,000 shares on 2/14/2023Ownership: 0.000%Cutler Group LLC CASold 17,800 shares on 2/7/2023Ownership: 0.000%Wolverine Asset Management LLCSold 100,100 shares on 2/1/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CLVS Stock - Frequently Asked Questions Should I buy or sell Clovis Oncology stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares. View CLVS analyst ratings or view top-rated stocks. How were Clovis Oncology's earnings last quarter? Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to analyst estimates of $38.73 million. During the same period last year, the company earned ($0.89) EPS. What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO? 12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Clovis Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). What is Clovis Oncology's stock symbol? Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS." Who are Clovis Oncology's major shareholders? Clovis Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.00%), Aristeia Capital LLC (0.00%), Susquehanna International Group LLP (0.00%), Cutler Group LLC CA (0.00%), Bank of Montreal Can (0.00%) and Wolverine Asset Management LLC (0.00%). Insiders that own company stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding. View institutional ownership trends. What is Clovis Oncology's stock price today? One share of CLVS stock can currently be purchased for approximately $0.08. How much money does Clovis Oncology make? Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $11.60 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis. How can I contact Clovis Oncology? Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360. This page (NASDAQ:CLVS) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.